NCT06524570 2026-02-18
iFOCUS
UMC Utrecht
Phase 1 Recruiting
Clinical Trials
11 trialsNCT04417465 2025-09-25
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
AbbVie
Phase 1 Completed
NCT03425279 2025-09-23
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
BioAtla, Inc.
Phase 1/2 Completed
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT03868046 2025-04-01
AUTENTIC
Hospital Universitario Araba
Completed
NCT05934214 2024-03-05
EXIT
Groupe Hospitalier Pitie-Salpetriere
Completed
NCT06047860 2023-09-21
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT03790488 2023-07-03
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
Jounce Therapeutics, Inc.
Phase 1 Completed
NCT05790447 2023-03-30
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05322187 2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3 Unknown
NCT03492242 2019-09-26
CHIMeRA
Groupe Hospitalier Pitie-Salpetriere
Completed